Q4 2024 Nano-X Imaging Ltd Earnings Call Transcript
Key Points
- Nano X Imaging Ltd (NNOX) achieved significant regulatory milestones, including FDA general use clearance and CE mark designation for the Nanox.ARC system.
- The company is expanding its market presence in the US and Europe, with new distribution agreements and strategic partnerships.
- Positive feedback from initial customers and early adopters of the Nanox.ARC system indicates strong market interest and potential for growth.
- The company's AI solutions are gaining traction, with new customer engagements and collaborations in the US and Europe.
- Nano X Imaging Ltd (NNOX) is making progress in clinical trials and data generation, which supports the clinical value and adoption of its imaging technology.
- The company reported a GAAP net loss of $14.1 million for the fourth quarter of 2024, an increase from the previous year.
- Revenue from AI solutions remains relatively low, with a gross loss reported for the period.
- There is uncertainty regarding the timing of the inflection point for significant revenue growth from imaging solutions.
- Operating expenses have increased, particularly in general and administrative costs, due to higher legal expenses.
- The company does not provide specific guidance on future financial performance, creating uncertainty for investors.
Good day, and thank you for standing by. Welcome to the Nano-X fourth-quarter 2024 earnings call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to Mike Cavanaugh, Investor Relations. Please go ahead.
Good morning and thank you for joining us today. Earlier today, Nano-X Imaging Limited released financial results for the quarter ended December 31, 2024. The release is currently available on the investors section of the company's website.
With me today are Erez Meltzer, Chief Executive Officer and Acting Chairman; and Ran Daniel, Chief Financial Officer.
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements regarding the company's financial results, research and development, manufacturing and commercialization activities, regulatory process and clinical activities and other matters.
These
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
